semaglutide afib Effect of on Atrial Arrhythmias Recurrence Following Ablation for Atrial Fibrillation: A Prospective Study Semaglutide versus placebo in people

Zhang X., et al., 2020 J Cell Physiol 235 (4):3425-3437

The mean BMI of the cohort was 37 kg/m 2

Participants taking the drug, called orforglipron, lost an average of 9.4% to 14.7% of their body weight, depending on the dose given, after 36 weeks, according to the phase 2 clinical trial results, which were published in the New England Journal of Medicine

The long-term safety of glutathione injections is still being researched

Up to 60% of NENs are reported to express high levels of GLP-1R, raising the possibility that GLP-1 agonists could promote tumor growth in NENs

IDH catalyzes the oxidative decarboxylation of isocitrate to -KG